Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)
ArchivedNational Institutes of Health
Description
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics and related countermeasures against antibiotic resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, or Candida auris. Applications must include a Product Development Strategy attachment. Substantive investment by industrial participants is highly encouraged.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
NIH OER Webmaster<br/>OERWebmaster03@od.nih.gov
OERWebmaster03@od.nih.gov
- PostedApr 5, 2022
- ClosesJul 29, 2022
- Award ceiling$650,000
- CFDA93.855
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro